Unknown

Dataset Information

0

Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury.


ABSTRACT: Acute kidney injury (AKI) is a common, severe emergency case in clinics, with high incidence, significant mortality and increased costs. Despite development in the understanding of its pathophysiology, the therapeutic choices are still confined to dialysis and renal transplantation. Considering their antiapoptotic, immunomodulatory, antioxidative and pro-angiogenic effects, mesenchymal stem cells (MSCs) may be a promising candidate for AKI management. Based on these findings, some clinical trials have been performed, but the results are contradictory (NCT00733876, NCT01602328). The low engraftment, poor survival rate, impaired paracrine ability and delayed administration of MSCs are the four main reasons for the limited clinical efficacy. Investigators have developed a series of preconditioning strategies to improve MSC survival rates and paracrine ability. In this review, by summarizing these encouraging studies, we intend to provide a comprehensive understanding of various preconditioning strategies on AKI therapy and improve the prognosis of AKI patients by regenerative medicine.

SUBMITTER: Zhao L 

PROVIDER: S-EPMC6349184 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury.

Zhao Lingfei L   Hu Chenxia C   Zhang Ping P   Jiang Hua H   Chen Jianghua J  

Journal of cellular and molecular medicine 20181128 2


Acute kidney injury (AKI) is a common, severe emergency case in clinics, with high incidence, significant mortality and increased costs. Despite development in the understanding of its pathophysiology, the therapeutic choices are still confined to dialysis and renal transplantation. Considering their antiapoptotic, immunomodulatory, antioxidative and pro-angiogenic effects, mesenchymal stem cells (MSCs) may be a promising candidate for AKI management. Based on these findings, some clinical trial  ...[more]

Similar Datasets

| S-EPMC6108125 | biostudies-literature
| S-EPMC7135682 | biostudies-literature
| S-EPMC7245776 | biostudies-literature
| S-EPMC9124131 | biostudies-literature
| S-EPMC4186414 | biostudies-literature
| S-EPMC7453612 | biostudies-literature
| S-EPMC8342149 | biostudies-literature
| S-EPMC4588407 | biostudies-literature
| S-EPMC7995150 | biostudies-literature
| S-EPMC5040900 | biostudies-literature